Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial
The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.
We haven't written up this one. CNBC World has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.